SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets tentative approval from USFDA for Tadalafil Tablets

19 Jun 2018 Evaluate

Zydus Cadila has received the tentative approval from the US Food and Drug Administration (USFDA) to market Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg. It is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

929.25 0.40 (0.04%)
22-Apr-2026 13:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1663.10
Dr. Reddys Lab 1224.45
Cipla 1235.20
Zydus Lifesciences 929.25
Lupin 2310.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×